** Shares of cancer drug developer Tempest Therapeutics TPST.O rise ~9% to $7.79 in extended trading
** TPST says it is exploring strategic alternatives, such as mergers or partnerships, to advance its cancer treatment programs
** Company's pipeline includes its lead liver cancer drug, amezalpat, and TPST-1495, a treatment for familial adenomatous polyposis, a rare genetic disorder
** Amezalpat received both Orphan Drug and Fast Track designations from the US FDA
** As of last close, stock down 34% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。